Soft tissue sarcomas (STS) exhibit a high rate of relapse despite standard systemic and locoregional therapies. Due to the heterogeneity of STS subtypes, complex genetic mutation profiles, and lack of tumor markers in sarcoma, surveillance for detection of early recurrence is currently limited to cross-sectional imaging. Circulating tumor DNA (ctDNA) has emerged as a noninvasive and dynamic tool to detect molecular disease shed from tumor tissue into the bloodstream. It currently has applications in postoperative monitoring of colorectal, lung, and breast cancers, but its role in sarcoma is not well understood.
1‐4 This study evaluates the use of tumor-informed ctDNA profiling as a potential adjunct to monitor disease in STS. …
